Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25524798

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Jan
First author
Finn RS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Jan;16(1):2-3. doi: 10.1016/S1470-2045(14)71188-X.
    note
    Source null
    related pmid
    25524801
    relationship
    Comment in

Authors and identifiers

  1. name
    Finn RS
    type
    Author
  2. name
    Crown JP
    type
    Author
  3. name
    Lang I
    type
    Author
  4. name
    Boer K
    type
    Author
  5. name
    Bondarenko IM
    type
    Author
  6. name
    Kulyk SO
    type
    Author
  7. name
    Ettl J
    type
    Author
  8. name
    Patel R
    type
    Author
  9. name
    Pinter T
    type
    Author
  10. name
    Schmidt M
    type
    Author
  11. name
    Shparyk Y
    type
    Author
  12. name
    Thummala AR
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Finn RS
    type
    Author
  2. name
    Crown JP
    type
    Author
  3. name
    Lang I
    type
    Author
  4. name
    Boer K
    type
    Author
  5. name
    Bondarenko IM
    type
    Author
  6. name
    Kulyk SO
    type
    Author
  7. name
    Ettl J
    type
    Author
  8. name
    Patel R
    type
    Author
  9. name
    Pinter T
    type
    Author
  10. name
    Schmidt M
    type
    Author
  11. name
    Shparyk Y
    type
    Author
  12. name
    Thummala AR
    type
    Author
bibliography ids
  1. nci-bib-192d8b199f48d448c70cc162
book metadata
content sha256
52476489f4cbb20b2a1d987ad3ea891a6f288f098d1bccac28e0946f5aa5d6cf
document type
citation
dois
  1. 10.1016/S1470-2045(14)71159-3
electronic publication date
display
2014 Dec 16
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:25524798
immutable id
pubmed:25524798@52476489f4cbb20b2a1d987ad3ea891a6f288f098d1bccac28e0946f5aa5d6cf
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
25-35
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Jan;16(1):2-3. doi: 10.1016/S1470-2045(14)71188-X.
    note
    Source null
    related pmid
    25524801
    relationship
    Comment in
outcomes validated
false
pmid
25524798
provenance
batch id
863b068fe5a07222af6a
provider
NCBI PubMed ESummary
record sha256
79198da5c1fa22e5d724844104110bd8923f6f8b76a99ba896823a066ff20264
response sha256
80b1cc99e93fcfceb3e1b12ea433c615b032a2db13a615db7a6e9382c17c5034
retrieved at
2026-09-09T23:47:07.648963+00:00
publication date
display
2015 Jan
precision
month
year
2015
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
  6. Research Support, U.S. Gov't, Non-P.H.S.
  7. Video-Audio Media
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25524798/
title
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Preserved source evidence · Not medical advice